Literature DB >> 27486812

A Meta-Analysis for Effects of Elevated Pre-Transplantation Serum Ferritin on the Outcomes in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Wenjian Guo1,2, Aishu Dong2, Muqing He2, Xiaoji Lin2, Rongxing Yao2, Baolin Zhu2, Xiahui Pan2, Jin Jie1.   

Abstract

The level of pre-transplantation serum ferritin (SF) is one of the factors related to outcome for patients undergoing allogeneic hematopoietic stem cell transplantation. We searched PubMed and Cochrane Library databases from 2000 to 2014. The primary efficacy outcome was overall survival rate and non-relapse mortality. Twenty clinical trials were selected from 189 studies identified. The combined hazard ratio indicated a significantly lower overall survival rate and a higher non-relapse mortality rate in patients with elevated SF before transplantation. This indicates that elevated pre-transplantation SF affects outcome in patients undergoing allogeneic hematopoietic stem cell transplantation.

Entities:  

Keywords:  Hematopoietic stem cell transplantation; Non-Relapse mortality; Overall survival; Serum ferritin

Mesh:

Substances:

Year:  2016        PMID: 27486812     DOI: 10.1080/07357907.2016.1197236

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  2 in total

Review 1.  Effect of pre-transplantation serum ferritin on outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation: A meta-analysis.

Authors:  Zhengwei Yan; Xianying Chen; Huiping Wang; Yaling Chen; Lihong Chen; Peilin Wu; Wei Wang
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

2.  Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia.

Authors:  Byung-Sik Cho; Young-Woo Jeon; A-Reum Hahn; Tai-Hyang Lee; Sung-Soo Park; Jae-Ho Yoon; Sung-Eun Lee; Ki-Seong Eom; Yoo-Jin Kim; Seok Lee; Chang-Ki Min; Seok-Goo Cho; Jong-Wook Lee; Woo-Sung Min; Hee-Je Kim
Journal:  Cancer Med       Date:  2019-01-24       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.